+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Dermatophytic Onychomycosis: Epidemiology Forecast to 2028

  • ID: 5004130
  • Report
  • January 2020
  • Region: Global
  • 18 pages
  • GlobalData
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 2
Dermatophytic Onychomycosis: Epidemiology Forecast to 2028

Summary

Dermatophytic onychomycosis (DO) is a form of chronic fungal infection of the nails caused by dermatophytes, a type of fungi that requires keratin for growth (Aly, 1994; Elewski, 1998). The disease can occur in both fingernails and toenails, though it is most commonly found affecting the toes, and predominantly affects adults ages 30-60 years (Elewski and Charif, 1997). Symptoms of this disease can include nail discoloration, thickening of the nail, splitting of the nail, separation of the nail from the nail bed, and overall discomfort in the affected area (Rogers and Bassler, 2001).

In 2018, there were 24,061,831 total prevalent cases of DO and 9,624,733 diagnosed prevalent cases of DO in the US, in men and women, combined for all ages. By 2028 these numbers are expected to grow to 31,498,328 and 12,599,329, respectively. Men accounted for more than 60% of the cases in the US in 2018 and adults ages 60-69 years comprise the largest number of cases in the ten-year age groupings captured in this forecast, with more than 30% of the diagnosed prevalent cases of DO.

forecast is strengthened by the use of peer-reviewed publications to forecast the total prevalent cases of DO in the US. Additionally, this forecast is strengthened by the US of primary market research, through a prescriber survey, to estimate the diagnosis rate of DO in the US.

Scope
  • The Dermatophytic Onychomycosis (DO) Epidemiology Report provides an overview of the risk factors and historical trends of DO in the US.
  • This report provides an overview of the risk factors and the global and historical trends for DO in the US. It also includes a 10-year epidemiology forecast of the total and diagnosed prevalent cases of DO in the US from 2018 to 2028.
  • The diagnosed prevalent cases are further segmented by sex and age (in ten year age groups starting at 0 years and up to 80 years and older).
  • The DO epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
  • The Epidemiology Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the US.
  • The Epidemiology report is easy to navigate, interactive with dashboards, and epidemiology-based with transparent and consistent methodologies. Moreover, the report supports data presented in the report and showcases disease trends over a 10-year forecast period using reputable sources.
Reasons to buy

The DO Epidemiology series will allow you to:
  • Develop business strategies by understanding the trends shaping and driving the DO market in the US.
  • Quantify patient populations in the US DO market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for DO therapeutics in in the US.
Note: Product cover images may vary from those shown
2 of 2
1.1 List of Tables
1.2 List of Figures

2 Dermatophytic Onychomycosis: Executive Summary
2.1 Catalyst
2.2 Related Reports
2.3 Upcoming Reports

3 Epidemiology
3.1 Disease Background
3.2 Risk Factors and Comorbidities
3.3 Historical Trends
3.4 Forecast Methodology
3.4.1 Sources
3.4.2 Forecast Assumptions and Methods
3.5 Epidemiological Forecast for DO (2018-2028)
3.5.1 Total Prevalent Cases of DO
3.5.2 Diagnosed Prevalent Cases of DO
3.5.3 Sex-Specific Diagnosed Prevalent Cases of DO
3.5.4 Age-Specific Diagnosed Prevalent Cases of DO
3.6 Discussion
3.6.1 Epidemiological Forecast Insight
3.6.2 Limitations of Analysis

4 Appendix
4.1 Bibliography
4.2 Primary Research - Prescriber Survey
4.3 About the Authors
4.3.1 Epidemiologist
4.3.2 Reviewers
4.3.3 Global Director of Therapy Analysis and Epidemiology
4.3.4 Global Head and EVP of Healthcare Operations and Strategy
4.4 About the Publisher
4.5 Contact Us
4.6 Disclaimer

List of Tables
Table 1: Summary of Newly Added Data Types
Table 2: Summary of Updated Data Types
Table 3: Risk Factors and Comorbidities for DO
Table 4: High-Prescribing Physicians (non-KOLs) Surveyed, By Country

List of Figures
Figure 1: US, Diagnosed Prevalent Cases of DO, Men and Women, All Ages, 2018 and 2028
Figure 2: US, Total Prevalent Cases of DO, Men and Women, All Ages, 2018-2028
Figure 3: US, Diagnosed Prevalent Cases of DO, Men and Women, All Ages, 2018-2028
Figure 4: US, Diagnosed Prevalent Cases of DO, by Sex, All Ages, 2018
Figure 5: US, Diagnosed Prevalent Cases of DO, by Age, Men and Women, 2018
Note: Product cover images may vary from those shown
3 of 2

Loading
LOADING...

Adroll
adroll